• DILIsym web promo

    DILI-sim on UNC-TV: The Liver Takes it All

    UNC-TV Broadcast story on the DILI-sim Initiative



  • DILIsym_Process_DSS_promo

    DILIsym Services, Inc. Launched

    This spinout from the efforts of the DILI-sim Initiative will focus on proprietary simulation projects for pharma 
  • Highlighted Liver-560x310

    Daiichi Sankyo Joins The DILI-sim Initiative

    Japan-based pharma becomes newest member company of The DILI-sim Consortium


DILIsym®: An In Silico Model of Drug-Induced Liver Injury 

DILIsym® is a “middle-out”, multi scale computational model of drug-induced liver injury (DILI). The software is designed to be used during drug development to provide an enhanced understanding of the DILI hazard posed by individual molecules and to provide deeper insight into the mechanisms responsible for observed DILI responses at various stages of the development process.

Dr. Paul WatkinsThe DILI-sim Initiative is a consortium of life science companies led by DILIsym Services, Inc. and charged with developing the DILIsym® software. The goals of the Initiative are to improve patient safety, reduce the need for animal testing, and reduce the costs and time necessary to develop new drugs.

The Initiative is led by Dr. Paul B. Watkins, Director of the University of North Carolina Institute for Drug Safety Sciences, located in the heart of Research Triangle Park, North Carolina. 

Companies Supporting DILIsym® Software Development

2016 04 DILIsim Consortium 2